Arcutis (ARQT) director exercises options, sells over 40k shares

Arcutis Biotherapeutics (ARQT) director Neha Krishnamohan reported option exercises and share sales.

Rhea-AI Filing Summary

Arcutis Biotherapeutics (ARQT) director Neha Krishnamohan reported option exercises and share sales. On 11/13/2025, she exercised stock options to acquire 27,052 shares at $8.63 and 12,220 shares at $7.51 per share, then sold 39,272 shares at a weighted average price of $23.1896 and an additional 1,232 shares at $23.37.

After these transactions, she directly owned 22,123 shares of Arcutis common stock. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, with an end date of November 2, 2026, which is designed to allow insiders to sell shares according to a preset schedule.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Krishnamohan Neha

Role Director

Sold 40,504 shs ($939K)

Approx. gross sale proceeds $939K

Approx. exercise cost $325K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	27,052	$0.00	$0.00
Exercise	Stock Option (right to buy)	12,220	$0.00	$0.00
Exercise	Common Stock	27,052	$8.63	$233K
Exercise	Common Stock	12,220	$7.51	$92K
Sale	Common Stock	39,272	$23.1896	$911K
Sale	Common Stock	1,232	$23.37	$29K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 22,123 shares (Direct)

Footnotes (4)

1. F1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
4. F4. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARQT director Neha Krishnamohan report?

Neha Krishnamohan reported exercising stock options and selling Arcutis Biotherapeutics (ARQT) shares on 11/13/2025, changing her directly held share balance.

How many Arcutis (ARQT) options did the director exercise and at what prices?

She exercised options for 27,052 shares at $8.63 per share and 12,220 shares at $7.51 per share of Arcutis common stock.

How many Arcutis (ARQT) shares did the director sell and at what prices?

She sold 39,272 shares at a weighted average price of $23.1896 and 1,232 shares at $23.37. The weighted average sale price reflects multiple trades between $22.86 and $23.60.

How many Arcutis (ARQT) shares does the director own after these transactions?

Following the reported trades, Neha Krishnamohan directly owned 22,123 shares of Arcutis Biotherapeutics common stock.

Was the ARQT insider trading activity under a Rule 10b5-1 plan?

Yes. The transactions were executed under a Rule 10b5-1 trading plan adopted on August 14, 2025, with a plan end date of November 2, 2026.

What are the key terms of the director’s Arcutis stock options?

One stock option for 27,052 shares at $8.63 vests 100% on the first anniversary of June 14, 2024, and another for 12,220 shares at $7.51 vests 100% on the first anniversary of May 31, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 07:56 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krishnamohan Neha

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		M(1)		27,052	A	$8.63	50,407	D
Common Stock	11/13/2025		M(1)		12,220	A	$7.51	62,627	D
Common Stock	11/13/2025		S(1)		39,272	D	$23.1896(2)	23,355	D
Common Stock	11/13/2025		S(1)		1,232	D	$23.37	22,123	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.63	11/13/2025		M(1)			27,052	(3)	06/14/2034	Common Stock	27,052	$0	0	D
Stock Option (right to buy)	$7.51	11/13/2025		M(1)			12,220	(4)	05/31/2033	Common Stock	12,220	$0	0	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

4. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Neha Krishnamohan	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.